[ivory-search id="184" title="Recordati AJAX Search Form"]

Our Story

Recordati established rare diseases operations in the Nordic and Baltic regions in 2007 as part of Recordati Rare Diseases. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.

Our Story

Recordati was established in the Nordic and Baltic regions with the rare diseases portfolio in 2007 due to the acquisition of Orphan Europe. In 2018 the Recordati Speciality and Primary Care business unit was incorporated together with the Rare Disease business unit in Recordati AB. Today Recordati AB operates across the Nordic and Baltic regions from our regional office in Stockholm, Sweden.

Recordati will bring treatment options across specialty and primary care and rare diseases business units, and has operations worldwide, including here in the Nordics-Baltics with a well-diversified portfolio of prescription drugs, available to healthcare professionals and patients, and offered in most Nordics-Baltics markets.

Our purpose and corporate philosophy is to give people the opportunity to unlock the full potential of life and to bring a brighter future to patients across the world.

We believe that health, and the opportunity to live life to the fullest, is a right, not a privilege.

Specialty and Primary care Nordics focuses mainly on the following therapeutical areas: cardiovascular, central nervous system, gastrointestinal, urological.

Learn More

Recordati is a global international pharmaceutical company, Headquartered in Milan, Italy and listed on the Italian stock exchange. With over 4,450 employees, we develop and commercialise medicines to serve people living with common diseases, as well as those living with some of the rarest, in around 150 countries.

 

The Nordics-Baltics headquarter operates from Stockholm and consists of 24 employees within commercial, medical, finance, supply chain, regulatory and QA.

Focused on the few.

 

The Rare Diseases business unit is focused on providing the most effective treatment for unmet medical needs, mainly of genetic origin and caused by metabolic disorders, endocrine diseases, rare oncology pathologies.

Underpinned by a history of strong financial delivery, we will continue to grow from within, capture opportunities within our own pipeline, and identify opportunities to bring in new treatments through partnerships & acquisitions across all our businesses.

MILESTONES

1926

Giovanni Recordati founds the Laboratorio Farmacologico Reggiano in Correggio (RE, Italy)

1953

Transfer of headquarters to Milan

1961

Recordati – Syntex (now part of Roche) licence agreement. Located in Silicon Valley, Syntex was a pioneering company in the study and synthesis of steroid hormones

1963

Inauguration of the pharmaceutical chemical plant in Campoverde di Aprilia

1984

Listing on the Italian Stock Exchange

1995

Beginning the process of internationalisation – Establishment of a subsidiary in Spain, now called Casen Recordati

1999

Acquisition of Doms Adrian (France)

2000

Acquisition of Bouchara (France)

2001

Establishment of Bouchara Recordati in France

2005
  • Acquisition of Merckle Recordati in Germany, now Recordati Pharma
  • Establishment of Recordati Pharmaceuticals in the United Kingdom
  • Establishment of Recordati Hellas in Greece
  • Establishment of the new pharmaceutical chemical plant in Cork, Ireland
2006

Acquisition of the Grupo Jaba companies in Portugal, today Jaba Recordati

2007

Entry to the rare diseases sector with the acquisition of Orphan Europe, now Recordati Rare Diseases

2008
  • Acquisition of FIC and FIC Médical, dedicated to the registration and promotion of pharmaceutical products in Russia and other Commonwealth of Independent States (C.I.S.) countries
  • Acquisition of Yeni Ilaç in Turkey, today Recordati Ilaç
2009

Acquisition of Herbacos-Bofarma in the Czech Republic and Slovakia, today Herbacos Recordati

2010

Acquisition of ArtMed International in Romania, now Recordati Romania

2011

Acquisition of Dr. F. Frik Ilaç in Turkey, now Recordati Ilaç

2012
  • Entry into the US market rare diseases sector
  • Acquisition of product portfolio for the treatment of a number of rare diseases in the US
  • Acquisition of Farma-Projekt in Poland, now Recordati Polska
2013
  • Acquisition of Opalia Pharma and its cGMP certified production facilities in Tunisia, now Opalia Recordati
  • Acquisition of Laboratorios Casen Fleet and its cGMP certified production facilities in Spain, now Casen Recordati
2015

Establishment of new subsidiaries in Brazil, Mexico and Colombia 

2016
  • SPC and OTC portfolio strengthened
  • Acquisition of Italchimici in Italy
  • Acquisition of Pro Farma AG, now Recordati AG, in Switzerland and Austria
2017
  • Acquisition of Natural Point in Italy
  • Acquisition of Tonipharm in France 
  • Establishment of new subsidiaries in Japan and Australia
2019
  • Expansion of the rare diseases product portfolio: entry into the endocrinology sector
  • Establishment of Recordati Bulgaria
2022
  • Acquisition of EUSA Pharma (UK) Ltd, a global specialist pharmaceutical company focused on rare diseases and niche oncology
2023

  • Recordati announces an agreement with GSK to commercialize Avodart® (dutasteride) and Combodart®/Duodart®

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global careers website

Go to Website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

Go to Website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

Go to Website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

Go to Website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

Go to Website

You are now leaving Recordati Nordic’s and Baltic’s page and will be linked to the Recordati global website

Go to Website

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: INVER@recordati.it;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.